

Memorial Sloan Kettering Cancer Center  
is pleased to announce:

# Practical Management Strategies and New Innovations in Prostate Radiotherapy



*Featuring World Renowned  
Speakers Covering  
Cutting-Edge Topics*

Thursday-Friday  
**December 8-9, 2016**

**CALL FOR  
ABSTRACTS**

**Conference Location:**

Memorial Sloan Kettering Cancer Center  
Zuckerman Research Center  
417 East 68th Street New York, NY 10065



Memorial Sloan Kettering  
Cancer Center



## Course Overview

The course will include coverage of the following topics:

- Comparing outcomes for surgery and radiotherapy in clinically localized disease
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for Prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of Prostate Cancer
- Salvage radiotherapy after primary treatment failures and Expected Toxicity Outcomes
- Optimal Integration of Hormonal therapy with Prostate Radiotherapy
- New Developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring Target and Nodal Regions
- Integrating imaging into Treatment Selection and Treatment Planning

### TARGET AUDIENCE

The target audience includes Radiation Oncologists, Urologists, Medical Oncologists, Medical Physicists, Radiation Therapists, Nurses and Residents.

### CALL FOR ABSTRACTS

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. **The deadline for abstract submissions is 9/15/16.** Visit the conference website for more information: [www.mskcc.org/radiotherapy](http://www.mskcc.org/radiotherapy).

## Course Faculty


### MSK COURSE DIRECTOR



**Michael J. Zelefsky MD**

Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

### MSK CO-COURSE DIRECTOR



**Marisa A. Kollmeier MD**

Radiation Oncologist, Attending



**Sean McBride MD MPH**

Radiation Oncologist, Attending

### MSK FACULTY

**Oguz Akin MD**  
Radiologist

**Stefan Both PhD**  
Dept. of Medical Physics

**Oren Cahlon MD**  
Radiation Oncologist  
Director, Proton Therapy

**Gilad Cohen MS**  
Senior Radiotherapy Physicist

**Jonathan Coleman MD**  
Urologist

**James Eastham MD FACS**  
Surgeon; Chief, Urology Service; Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology

**Richard M. Gewanter MD**  
Radiation Oncologist  
Chief, Commack/Rockville Center Radiation Oncology

**Laura Happersett MS**  
Radiotherapy Physicist, Sr., Dept of Medical Physics

**Margie A. Hunt MS**  
Chief, Clinical Physics Service

**Philip Kantoff MD**  
Medical Oncologist  
Chair, Department of Medicine; George J. Bosl Chair

**James G. Mechalakos PhD**  
Section Head of External Beam Treatment, Dept. of Medical Physics

**Michael J. Morris MD**  
Medical Oncologist

**John P. Mulhall MD**  
Director, Male Sexual and Reproductive Medicine Program

**Simon N. Powell MD PhD FRCR**  
Radiation Oncologist  
Chair, Department of Radiation Oncology; Enid A. Haupt Chair in Radiation Oncology

**Jaspreet S. Sandhu MD**  
Urologic Surgeon

**Susan F. Slovin MD PhD**  
Medical Oncologist

**Neelam Tyagi PhD**  
Assistant Attending Physician, Dept of Medical Physics

**Herbert Alberto Vargas MD**  
Radiologist

**Wolfgang A. Weber MD**  
Nuclear Medicine Physician  
Chief, Molecular Imaging and Therapy Service

### INVITED FACULTY

**Kristy Brock-Leatherman PhD**  
Associate Professor, Nuclear Engineering & Radiological Sciences; Associate Professor, Radiation Oncology; Associate Professor, Biomedical Engineering, University of Michigan

**Juanita Crook MD**  
Radiation Oncologist, BC Cancer Foundation Agency

**Anthony Victor D'Amico MD PhD**  
Professor, Radiation Oncology, Harvard Medical School; Chief, Genitourinary Radiation Oncology, Brigham And Women's Hospital; Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute

**Mark Emberton MD FRCS Urol**  
Dean, Faculty of Medical Sciences, University College London

**Steven Jay Frank MD**  
Associate Professor, Dept of Radiation Oncology, MD Anderson Cancer Center

**Carri Glide-Hurst PhD**  
Senior Staff Physicist, Henry Ford Hospital

**Carlo Greco MD**  
Director of Clinical Research, Champalimaud Centre for the Unknown, Lisbon, Portugal

**Peter Hoskin MD**  
Consultant Clinical Oncologist, East and North Hertfordshire NHS Trust

**Patrick McLaughlin MD**  
Medical Oncologist, University of Michigan

**Jeff Michalski MD MBA**  
Professor, Radiation Oncology; Vice Chairman, Radiation Oncology; Chief, Genitourinary Service, Washington University in St. Louis

**Allan Pollack MD PhD**  
Professor and Chairman of Radiation Oncology, University of Miami

**Mack Roach MD**  
Professor & Chair, Department of Radiation Oncology, and Professor, Department of Urology, University of California, San Francisco

**Howard Sandler MD MS**  
Chair, Radiation Oncology, Cedars-Sinai Medical Center

**Matthew Smith MD PhD**  
Professor, Medicine, Harvard Medical School; Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital

**Robert Timmerman MD**  
Professor, Radiation Oncology, Neurological Surgery, University of Texas, Southwestern

**Anthony Laurence Zietman MD**  
Associate Director, Harvard Radiation Oncology Residency Program; Director, GU Service, Massachusetts General Hospital

# Thursday, December 8, 2016

7:00-7:50 am	<b>BREAKFAST &amp; REGISTRATION</b>	3:15-4:15 pm	<b>Structure Contouring: Basic Anatomy and What's New?</b>
7:50-8:00 am	<b>Welcome &amp; Introduction</b> Michael J. Zelefsky MD		<b>MODERATOR</b> Sean McBride MD, MPH
	<b>SESSION A:</b> Comparative Outcomes and Toxicity Management		<ul style="list-style-type: none"><li><b>MRI Anatomy of the Prostate and Critical Normal Tissues</b> Patrick McLaughlin MD</li><li><b>Contouring Normal Tissue Structures with Confidence - Contouring the Pelvic nodes with confidence</b> Oguz Akin MD</li><li><b>Multi-modality Image Registration and Fusion: Evaluating uncertainty and building confidence</b> Kristy Brock-Leatherman PhD</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>
8:00-9:15 am	<b>Comparison of Outcomes and Toxicities and QOL between Treatment Interventions</b> MODERATOR Marisa A. Kollmeier MD	4:15-4:30 pm	<b>COFFEE BREAK</b>
	<ul style="list-style-type: none"><li><b>Comparison of Surgery and Radiotherapy for High Risk Disease: The Urologist's Perspective</b> James Eastham MD, FACS</li><li><b>Comparison of Surgery, EBRT and Brachytherapy Based Modalities for High Risk Disease - The Radiation Oncologist Perspective</b> Mack Roach MD</li><li><b>Comparison of Toxicity and QOL Outcomes between Surgery and Radiotherapeutic Interventions</b> Jeff Michalski MD, MBA</li><li><b>Panel Discussion - Q&amp;A</b></li></ul>	4:30-6:00 pm	<b>Advances in External Beam Treatment Planning and Delivery</b> MODERATOR Neelam Tyagi PhD
9:15-10:30 am	<b>Optimal Use of Androgen Deprivation Therapy (ADT) and Radiotherapy</b> MODERATOR Sean McBride MD, MPH		<ul style="list-style-type: none"><li><b>Guidelines for Target and Normal Tissue Dose Constraints for EBRT and SBRT</b> Laura Happerset MS</li><li><b>Refining the State-of-the-Art: Simulation through Treatment Planning: What are the New Treatment Planning Programs Able to Accomplish?</b> James G. Mechalakos PhD</li><li><b>Advances in Multi-Modality Image-Based Planning and MR-Based Simulation</b> Carri Glide-Hurst PhD</li><li><b>Treatment Delivery: Novel Approaches to Motion Reduction and Image Guidance</b> Margie A. Hunt MS</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>
10:30-11:00 am	<b>COFFEE BREAK</b>	6:00-6:45 pm	<b>Cocktail Reception &amp; Poster Presentations</b>
11:00-12:00 pm	<b>Optimizing Management of Side Effects after EBRT and Brachytherapy</b> MODERATOR Michael J. Zelefsky MD		
	<ul style="list-style-type: none"><li><b>Addressing GI Toxicity</b> Marisa A. Kollmeier MD</li><li><b>Addressing GU Toxicity</b> Jaspreet S. Sandhu MD</li><li><b>Addressing Sexual Dysfunction</b> John Mulhall MD</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>		
12:00-1:00 pm	<b>SESSION B:</b> Radiotherapy Treatment Interventions: Technical Aspects	7:30-8:00 am	<b>BREAKFAST</b>
	<b>Imaging for Prostate Cancer- Impact on Staging and Treatment Selection</b> MODERATOR Richard M. Gewanter MD	8:00-9:00 am	<b>Department of Medicine Grand Rounds</b> Biomarkers and Genomics for Prostate Cancer Philip Kantoff MD
	<ul style="list-style-type: none"><li><b>MP-MRI: Opportunities to Assess and Predict Treatment Response</b> Herbert Alberto Vargas MD</li><li><b>Molecular Imaging and Novel Tracers in Prostate Cancer</b> Wolfgang A. Weber MD</li><li><b>Putting It All Together: Using Imaging to Inform Treatment Options</b> Steven Jay Frank MD</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>	9:15-10:30 am	<b>SESSION C:</b> Novel Radiotherapy Treatment Interventions: Clinical Aspects
1:00-2:00 pm	<b>LUNCH BREAK</b>		<b>SBRT Outcomes and Advances</b> MODERATOR Michael J. Zelefsky MD
2:00-3:15 pm	<b>Brachytherapy: Indications, Tumor Control Outcomes and Toxicity and Advances in the OR</b> MODERATOR Marisa Kollmeier MD		<ul style="list-style-type: none"><li><b>Tumor Control Outcomes and Toxicity for SBRT</b> Michael J. Zelefsky MD</li><li><b>Moderate Hypofractionation</b> Allan Pollack MD, PhD</li><li><b>High Dose Fractionated SBRT</b> Robert Timmerman MD</li><li><b>Single Dose Radiotherapy for Localized Disease</b> Carlo Greco MD</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>
	<ul style="list-style-type: none"><li><b>LDR-Indications, Relative Contraindications, and Where Are We in 2016</b> Juanita Crook MD</li><li><b>HDR Indications, Relative Contraindications, and Where Are We in 2016</b> Peter Hoskin MD</li><li><b>Advances in the Operating Room: Real Time Treatment Assessments and Imaged Based Fusions for Dose Intensification</b> Michael J. Zelefsky MD</li><li><b>Optimal QA in the OR- Reducing Errors</b> Gilad Cohen MS</li><li><b>Panel Discussion and Q&amp;A</b></li></ul>	10:30-10:45 am	<b>COFFEE BREAK</b>

TO REGISTER TODAY, PLEASE VISIT:

[www.mskcc.org/Radiotherapy](http://www.mskcc.org/Radiotherapy)

# Friday, December 9, 2016



10:45-11:45 am

### Proton Therapy: Is there an Established Role in the Treatment of Localized Disease?

MODERATOR Oren Cahlon MS

- Clinical Outcomes & Toxicity and Tolerance Profiles and Comparison to Photon IMRT  
Anthony Laurence Zietman MD
- Treatment Planning Challenges  
Stefan Both PhD
- Cost Effectiveness of Protons versus Other Radiotherapeutic Interventions- Is there a Winner?  
Steven Jay Frank MD
- Panel Discussion and Q&A

11:45-1:00 pm

### Improving Our Radiotherapy Outcomes for Intermediate and High Risk Prostate Cancer

MODERATOR Anthony Laurence Zietman MD

- Important Considerations for Optimizing Outcomes for Local & Regional Therapy Using Radiotherapy in Intermediate and High Risk Disease  
Marisa A. Kollmeier MD
- Elective Lymph Node Irradiation for Prostate Cancer: When, How and Is it Worth it?  
Mack Roach MD
- Ongoing and Protocols in the Works for Prostate Cancer  
Howard Sandler MD, MS
- Strategies Incorporating Targeted Therapy and Novel Anti-androgen and Radiotherapy  
Sean McBride MD, MPH
- Panel Discussion and Q&A

1:00-1:45 pm

### LUNCH BREAK

## SESSION D: Salvage Therapy after Primary Treatment Failure

1:45-2:45 pm

### Salvage Radiotherapy after Surgery

MODERATOR Howard Sandler MD, MS

- Salvage versus Adjuvant Radiotherapy following Radical Prostatectomy  
Anthony Victor Damico MD, PhD
- Optimal Contouring and Treatment planning considerations in the Salvage Setting  
Allan Pollack MD PhD
- The Role of Hormonal Therapy in the Salvage Setting  
Anthony Laurence Zietman MD
- Panel Discussion and Q&A

2:45-3:45 pm

### Salvage Options after RT failure

MODERATOR Michael J. Zelefsky MD

- Outcomes with Brachytherapy as Salvage for Radio-Recurrent Disease  
Marisa A. Kollmeier MD
- Outcomes of Surgery and Other Approaches in the Salvage Setting  
Jonathan Coleman MD
- Focal Therapy Options and Outcomes  
Mark Emberton MD FRCS Urol
- Panel Discussion and Q&A

3:45 pm

### ADJOURN

# Registration

REGISTRATION FEES	EARLY Before 10/8/16	GENERAL After 10/8/16
MDs, PhDs, DOs, and Medical Physicists	\$400	\$500
MSK Alliance and MSK Alumni	\$280	\$350
Residents, Fellows, RNs, Medical Students and other Healthcare Providers	\$150	\$250
Industry Members*	\$875	\$875

\*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

TO REGISTER TODAY, PLEASE VISIT:

**[www.mskcc.org/Radiotherapy](http://www.mskcc.org/Radiotherapy)**

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

**Registration is complimentary for MSK staff who wish to attend this course.**  
However, you must register online by visiting the Continuing Medical Education page on [OneMSK](#).

**CONTACT** Continuing Medical Education  
Memorial Sloan Kettering Cancer Center  
633 Third Avenue, 12th Floor New York, New York 10017  
cme@mskcc.org

#### COURSE DESIGN

This course includes hands-on review of cases which will be intermixed with short didactic lectures.

#### EVALUATION

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

#### OUTCOMES MEASUREMENT SURVEY

Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

#### ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### AMA CREDIT DESIGNATION STATEMENT

MSK designates this live activity for a maximum of **15.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for **15.5 AMA PRA Category 1 Credit(s)™**.

#### FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

#### ACCOMMODATIONS

For information on hotels in the area of MSKCC with discounted rates, please visit: [www.mskcc.org/accommodations](#).



Memorial Sloan Kettering  
Cancer Center

CONTINUING MEDICAL EDUCATION  
633 Third Avenue, 12th Floor  
New York, New York 10017

# Practical Management Strategies and New Innovations in Prostate Radiotherapy

December 8-9, 2016

[www.mskcc.org/Radiotherapy](http://www.mskcc.org/Radiotherapy)